热门资讯> 正文

Lexicon获得Novo第三个1000万美元里程碑

2026-08-24 20:42

Lexicon Pharmaceuticals (LXRX) said it earned a third $10M milestone payment from Novo Nordisk after reaching a patient-dosing milestone in the Phase 1 trial of obesity drug candidate LX9851.
The payment brings Lexicon’s total milestone and upfront proceeds from the collaboration to $75M.
The company is eligible for up to $1 billion, plus royalties on future net sales.

More on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon anticipates Zynquista NDA resubmission in Q4 2026 as SONATA-HCM top line data expected in Q1 2027
Lexicon Pharmaceuticals GAAP EPS of -$0.07 misses by $0.02, revenue of $28.9M beats by $24.9M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。